Pfizer said a third shot would restore the effectiveness of its COVID-19 vaccine to about 95%.
Data released by Pfizer last week shows the two-dose vaccine regimen remains highly effective against severe cases of the disease even as its protection against symptomatic cases has waned, falling from about 96% to 84% after six months.The FDA signed off in August on a similar measurewho are at higher risk for severe disease. But the agency stopped short of recommending boosters for otherwise healthy people who are fully vaccinated, signaling a need for more data.
In a nonbinding vote last week, an outside advisory panel assembled by the FDA ruled 16-2 against providing third shots to the general population. “I don’t think a booster dose is going to significantly contribute to controlling the pandemic,” said Dr. Cody Meissner of Tufts University, who sits on the panel. “And I think it’s important that the main message we transmit is that we’ve got to get everyone two doses.”to more vulnerable segments of their population.to distribute additional doses in wealthy countries, calling for a moratorium.
“As we’ve seen from the emergence of variant after variant, we cannot get out of it unless the whole world gets out of it together,” said Dr. Bruce Aylward, a WHO special adviser. “And with the huge disparity in vaccination coverage, we’re simply not going to be able to achieve that.” Recipients of the Moderna and Johnson & Johnson COVID vaccines should stay tuned as the FDA weighs whether they will also need a booster.on Tuesday indicates the protection afforded by J&J’s vaccine doesn’t wane, unlike Pfizer and Moderna’s offerings, though a second shot would boost its efficacy against mild to severe COVID-19 from 74% up to 94%.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Covid-19: NI records four Covid-linked deaths, 1,060 casesThe total number of deaths linked to coronavirus in NI since the start of the pandemic is 2,517.
Weiterlesen »
Smaller COVID vaccine doses may protect children as well as full doses in adults: PfizerPfizer just released its first safety data about COVID-19 vaccines for children ages 5 to 11, reassuring parents that a safe and effective vaccine soon could be available for those younger than 12.
Weiterlesen »
Pfizer Study of Covid-19 Vaccine in Pregnant Women Delayed by Slow EnrollmentPfizer wanted to study its Covid-19 vaccine in pregnant women, but then the shots became widely available; “It’s hard to enthusiastically recommend the study when you’ve got a vaccine out there,” says one doctor
Weiterlesen »
U.S. CDC advisers could vote on Pfizer COVID-19 vaccine booster on ThursdayThe CDC's Advisory Committee on Immunization Practices (ACIP) is meeting on Sept 22-23 to discuss which Americans should get the third vaccine shot, should it be authorized for use by the Food and Drug Administration. Pfizer has asked the FDA to approve the third shot for all people aged 16 and over, but a panel of outside advisors to the FDA last Friday said there was only evidence for a shot being needed by people aged 65 and older.
Weiterlesen »
Pfizer Covid-19 Booster Shouldn’t Be for Moderna, J&J Vaccine Recipients, Health Official SaysAn FDA official told vaccine experts reviewing who should get an additional dose of Pfizer’s Covid-19 vaccine that there isn’t enough data to allow for mixing and matching of different shots
Weiterlesen »